These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 4039571)

  • 1. Bioavailability studies of etofibrate in rhesus monkeys.
    Waller AR; Chasseaud LF; Taylor T; Schatton W
    Arzneimittelforschung; 1985; 35(2):489-92. PubMed ID: 4039571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relative bioavailability of etofibrate. A comparison of an acute and a new sustained release formulation.
    Johnson KI; Hoppe HJ; Schatton W
    Arzneimittelforschung; 1984; 34(12):1785-7. PubMed ID: 6543315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disposition of etofibrate, clofibric and nicotinic acid esters, and their products in dogs.
    Garrett ER; Altmayer P
    J Pharm Sci; 1985 Mar; 74(3):295-9. PubMed ID: 4009437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Stability of antilipidemic etofibrate and its metabolites towards gastrointestinal and blood hydrolases (author's transl)].
    Oelschläger H; Rothley D; Ewert M; Nachev P
    Arzneimittelforschung; 1980; 30(6):984-8. PubMed ID: 7191278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of Etofibrate (Lipo-Merz) on "in vitro" cellular immune response and on lipid parameters of men with myocardial infarction and with arteriosclerosis obliterans.
    Horváth M; Varsányl M; Jovanovich N; Romics L; Gerö S
    Allergol Immunopathol (Madr); 1990; 18(2):95-9. PubMed ID: 2371944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Study of the antilipemic effect of etofibrate (Lipo-Merz)].
    Słowińska R; Bochenek W; Unlot J
    Pol Tyg Lek; 1983 Apr; 38(17):529-32. PubMed ID: 6356087
    [No Abstract]   [Full Text] [Related]  

  • 7. [Metabolism and pharmacokinetics of etofylline clofibrate, new antilipemic].
    Lücker PW; Wetzelsberger K; Erking W; Donike M
    Arzneimittelforschung; 1980; 30(11b):2045-53. PubMed ID: 7194058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concentration of clofibric acid in blood after the administration of delayed-release form of etofibrate.
    Vazquez Lopez F; Armijo Castro F; Pire Solis I; Gutierrez Fuentes JA
    Int J Clin Pharmacol Ther Toxicol; 1987 Jan; 25(1):31-5. PubMed ID: 3557726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasmolysis, red blood cell partitioning, and plasma protein binding of etofibrate, clofibrate, and their degradation products.
    Altmayer P; Garrett ER
    J Pharm Sci; 1983 Nov; 72(11):1309-18. PubMed ID: 6644594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictions of stability in pharmaceutical preparations XIX: Stability evaluation and bioanalysis of clofibric acid esters by high-pressure liquid chromatography.
    Garrett ER; Gardner MR
    J Pharm Sci; 1982 Jan; 71(1):14-25. PubMed ID: 7057373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacology and mechanism of action of etofibrate].
    Schatton W
    Med Welt; 1982 Sep; 33(38):1310-4. PubMed ID: 6752630
    [No Abstract]   [Full Text] [Related]  

  • 12. [Effectiveness of etofibrate in arteriosclerosis obliterans. Pilot study in hyperlipidemic patients with arteriosclerosis obliterans].
    Dembińska-Kieć A; Kostka-Trabka E; Grodzińska L; Bieroń K; Kedzior A; Basista M; Zmuda A; Trabka E; Slawiński M; Czarnecka H
    Fortschr Med; 1989 Jul; 107(20):450-2. PubMed ID: 2767596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Bile lipid composition in subjects with blood lipid disorders (types II and IV). Effect of a new hypolipemic drug (Etofibrate)].
    Altomonte L; Mingrone G; Ghirlanda G; Manna R; Rebuzzi A; Pala MA; Greco AV
    Minerva Med; 1980 Feb; 71(4):273-8. PubMed ID: 7354946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacy and safety of etofibrate in patients with non-proliferative diabetic retinopathy].
    Emmerich KH; Poritis N; Stelmane I; Klindzane M; Erbler H; Goldsteine J; Görtelmeyer R
    Klin Monbl Augenheilkd; 2009 Jul; 226(7):561-7. PubMed ID: 19644802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Atherosclerosis treatment with etofibrate retard. New perspectives].
    Degenring FH; Schatton W; Hotz W
    Fortschr Med; 1983 Aug; 101(30):1391-6. PubMed ID: 6618402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Studies with etofibrate in the rat. Part I: Effects on glycerol, free fatty acid and triacylglycerol metabolism.
    Herrera E; Lasunción MA; Castro M; Gómez-Coronado D; Martín A; Quack G
    Biochim Biophys Acta; 1988 Nov; 963(1):42-52. PubMed ID: 3179329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Confirmation of efficacy of etofibrate against peripheral atherosclerosis in non-human primates which model human lesion types I-VII.
    Fincham JE; Quack G; Wülfroth P; Benadé AJ
    Arzneimittelforschung; 1996 May; 46(5):519-25. PubMed ID: 8737639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioavailability of plafibride in healthy volunteers.
    Santaniello E; Conti F; Vilageliu J; Bruseghini L
    Arzneimittelforschung; 1981; 31(10a):1850-2. PubMed ID: 7198464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic approach of plafibride in rat.
    Zapatero D; Vilageliu J; Torres A; Ribalta JM; Bruseghini L
    Arzneimittelforschung; 1981; 31(10a):1800-4. PubMed ID: 7198457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [What is important in therapy of hyperlipoproteinemia. Lipo-Merz retard (etofibrate) lowers the atherogenic index].
    Fortschr Med; 1982 Sep; 100(35):1622-3. PubMed ID: 7173769
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.